产品
编 号：F740800
分子式：C23H25N5O4S
分子量：467.54
分子式：C23H25N5O4S
分子量：467.54
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 205256-55-9
产品详情
生物活性：
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
体内研究：
CT52923（口服；5、15、30 和 50 mg/kg；每日两次）可显著抑制大鼠颈动脉损伤后内膜新生的形成。Animal Model:Rat carotid artery balloon angioplasty model.
Dosage:5, 15, 30, and 50 mg/kg
Administration:Oral gavage; twice daily
Result:Inhibited PDGF-mediated response to vascular injury.
体外研究：
CT52923 抑制 PDGFRs 和干细胞因子受体，IC50 值为 100 至 200 nM。CT52923（0.01-30 μM；24 h）阻断血小板衍生生长因子诱导的平滑肌细胞迁移或成纤维细胞增殖，IC50 分别为 64 和 280 nM。
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
体内研究：
CT52923（口服；5、15、30 和 50 mg/kg；每日两次）可显著抑制大鼠颈动脉损伤后内膜新生的形成。Animal Model:Rat carotid artery balloon angioplasty model.
Dosage:5, 15, 30, and 50 mg/kg
Administration:Oral gavage; twice daily
Result:Inhibited PDGF-mediated response to vascular injury.
体外研究：
CT52923 抑制 PDGFRs 和干细胞因子受体，IC50 值为 100 至 200 nM。CT52923（0.01-30 μM；24 h）阻断血小板衍生生长因子诱导的平滑肌细胞迁移或成纤维细胞增殖，IC50 分别为 64 和 280 nM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备